BR112013023599A2 - método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-t - Google Patents

método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-t

Info

Publication number
BR112013023599A2
BR112013023599A2 BR112013023599-3A BR112013023599A BR112013023599A2 BR 112013023599 A2 BR112013023599 A2 BR 112013023599A2 BR 112013023599 A BR112013023599 A BR 112013023599A BR 112013023599 A2 BR112013023599 A2 BR 112013023599A2
Authority
BR
Brazil
Prior art keywords
epitope conjugate
cell carbohydrate
carbohydrate
cell
preparing
Prior art date
Application number
BR112013023599-3A
Other languages
English (en)
Other versions
BR112013023599B1 (pt
Inventor
Bay Sylvie
Leclerc Claude
Lo-Man Richard
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of BR112013023599A2 publication Critical patent/BR112013023599A2/pt
Publication of BR112013023599B1 publication Critical patent/BR112013023599B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Container Filling Or Packaging Operations (AREA)

Abstract

"método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato- 5 epítopo de célula-t" a presente invenção se refere a um método para preparar conjugados de carboidrato-epítopo de célula-t de fórmula (1): m(t-b)1, (i) na qual: m, t, b e n são como definidos na reivindicação 1.
BR112013023599-3A 2011-03-17 2012-03-16 Método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-t BR112013023599B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11290138.4 2011-03-17
EP11290138A EP2500033A1 (en) 2011-03-17 2011-03-17 Method for preparing muliple antigen glycopeptide carbohydrate conjugates
PCT/IB2012/051285 WO2012123926A1 (en) 2011-03-17 2012-03-16 Method for preparing multiple antigen glycopeptide carbohydrate conjugates

Publications (2)

Publication Number Publication Date
BR112013023599A2 true BR112013023599A2 (pt) 2019-05-07
BR112013023599B1 BR112013023599B1 (pt) 2023-01-10

Family

ID=44512239

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023599-3A BR112013023599B1 (pt) 2011-03-17 2012-03-16 Método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-t

Country Status (16)

Country Link
US (2) US20140378652A9 (pt)
EP (2) EP2500033A1 (pt)
JP (1) JP6006244B2 (pt)
KR (1) KR20140048107A (pt)
CN (1) CN103732246B (pt)
AU (1) AU2012227940A1 (pt)
BR (1) BR112013023599B1 (pt)
CA (1) CA2828688C (pt)
DK (1) DK2686009T3 (pt)
EA (1) EA201391202A1 (pt)
ES (1) ES2537180T3 (pt)
IL (1) IL228384A0 (pt)
MX (1) MX354325B (pt)
SG (1) SG193433A1 (pt)
WO (1) WO2012123926A1 (pt)
ZA (1) ZA201306219B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3410849B1 (en) 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
PT969873E (pt) 1997-03-27 2006-09-29 Pasteur Institut Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
CA2286798C (en) * 1997-04-16 2014-01-07 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof

Also Published As

Publication number Publication date
US20140378652A9 (en) 2014-12-25
WO2012123926A1 (en) 2012-09-20
DK2686009T3 (da) 2015-06-15
KR20140048107A (ko) 2014-04-23
EP2500033A1 (en) 2012-09-19
AU2012227940A1 (en) 2013-09-05
EP2686009A1 (en) 2014-01-22
SG193433A1 (en) 2013-10-30
ZA201306219B (en) 2014-05-28
US20170283466A1 (en) 2017-10-05
CA2828688C (en) 2021-08-03
ES2537180T3 (es) 2015-06-03
IL228384A0 (en) 2013-12-31
EP2686009B1 (en) 2015-04-29
MX2013010618A (es) 2014-04-14
JP6006244B2 (ja) 2016-10-12
MX354325B (es) 2018-02-26
JP2014510083A (ja) 2014-04-24
BR112013023599B1 (pt) 2023-01-10
EA201391202A1 (ru) 2014-03-31
CA2828688A1 (en) 2012-09-20
CN103732246A (zh) 2014-04-16
US20140171618A1 (en) 2014-06-19
CN103732246B (zh) 2017-06-30
US10899799B2 (en) 2021-01-26

Similar Documents

Publication Publication Date Title
ECSP14004976A (es) Anticuerpos anti-il-36r
PH12015500243B1 (en) Glycoconjugation processes and compositions
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
NZ703581A (en) Anti-cd70 antibody drug conjugates
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MY170719A (en) Antibody-drug conjugates
GT201300046A (es) Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3)
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
ECSP13012649A (es) Anticuerpos ANTI-IL-23
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
EA201490095A1 (ru) Новые производные майтанзиноида с пептидным линкером и их конъюгаты
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
CO7200270A2 (es) Azaindolcarboxamidas y azaindoltiocarboxamidas como insecticidas y acaricidas
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
BR112015000188A2 (pt) isolados de proteína de batata
BR112015004515A2 (pt) composição imunogênica
CY1118539T1 (el) Ανασυνδυασμενο μυκοβακτηριο ως εμβολιο
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
BR112012009310A2 (pt) composto, e, composição farmacêutica
MX362371B (es) Proceso para preparar 2-metoximetil-1,4-bencenodiamina y sales de esta.
GB2495884A (en) A method of increasing the effect of an activated-potentiated form of an antibody
DOP2015000007A (es) Métodos para preparar triazolopiridinas sutituidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: INSTITUT PASTEUR (FR) ; CENTRE NATIONAL DE LA RECH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/03/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.